慢性心不全の薬剤治療
1King's College Hospital NHS Foundation Trust, London, UK aamir.shamsi@nhs.net.
Drug and therapeutics bulletin
|September 4, 2025
まとめ
このレビューは,エジェクション分数減少 (HFrEF) による慢性心不全の管理のための4つの主要な薬物クラスについて詳細に述べています. HFrEF患者における最適な結果は,早期診断とこれらの薬による個別化された治療に依存します.
科学分野:
- 心臓病科
- 薬理学について
- 内科 医学
背景:
- 心不全 (HF) は,高い罹病率と死亡率を持つ進行症候群です.
- HFは英国におけるNHSの緊急入院の5%を占め,医療資源に大きな影響を及ぼします.
- 慢性心不全とエジェクション分数減少 (HFrEF) は,約60%のHF患者に影響します.
研究 の 目的:
- 慢性HFrEFの薬理学的治療をレビューする.
- HFrEF患者の管理における重要な考慮事項について議論する.
- 薬の管理,合併症の対処,生活習慣の変更の重要性を強調する.
主な方法:
- HFrEFの薬学的な治療戦略に重点を置く
- 4つの主要な薬剤の分類:ACE阻害剤/ARNI,ベータブロッカー,MRA,SGLT2i.
- これらの薬剤の相乗効果を強調する.
主要な成果:
- HFrEF治療の4つの柱は,ACE阻害剤/ARNI,β阻害剤,MRA,およびSGLT2iである.
- 個別化された治療と早期診断は 患者の治療結果にとって極めて重要です
- これらの薬剤を併用した治療は,患者の治療結果を改善します.
結論:
- 慢性HFrEFの効果的な管理は4つの主要な薬剤の組み合わせに依存しています.
- パーソナライズされた治療計画には これらの薬が不可欠です
- 総合的なケアには,薬の管理,合併症の対処,および改善されたHFrEFのアウトカムのためのライフスタイルの変更を促進します.
関連する概念動画
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:30Heart Failure IV: Classification and Diagnostic Evaluation
31
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
31
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434